Gladney will remain with the company as board chair, San Clemente, Calif.-based ReShape Lifesciences said.
The company’s board of directors said they will immediately begin to look for a replacement, according to an SEC filing.
AliveCor CEO Vic Gundotra is stepping away from his position at the head of the company, according to a recent CNBC report.
Gundotra, a former senior VP with Google, said it will remain active on AliveCor’s board as the Mountain View, Calif.-based company searches for an internal replacement, according to the report.
“I’m leaving the company in a position of strength,” Gundotra said, according to CNBC.
“We all love Vic. We sold hundreds of thousands of devices and continue to gain more traction, so all I can say is he did a great job,” founder & chief medical officer David Albert said, according to the report.
AliveCor has not yet officially commented on the leadership change.
Former finance and business services VP Rob Turnbull will take up the position of GM and oversee the reorganization of the company, according to the report.
Alongside the exit of the execs, the company will also be slashing its general workforce by 80%, according to the NZ Herald.
“While the reduction in workforce is very regrettable, our focus remains to develop the company as has originally been planned. In meeting our customers’ commercial requirements, we will continue to develop leading solutions in our space, and in this our R&D activity will continue to be run from our Auckland office,” Turnbull told the Herald.
Turnbull said that the company would further explain its reorganization plans next month, according to the report.
Functional Neuromodulation said this week said that it tapped current prez & COO Todd Langevin to succeed existing CEO Vincent Owens, effective January 25.
Prior to joining Functional Neuromodulation, Langevin held senior leadership roles at Medtronic and CVRx, including acting as VP and GM of Medtronic’s DBS movement disorders business and as the company’s neuromodulation European business director.
“Todd has been instrumental in leading the company through the ADvance I study, CE Mark approval, and IDE approval of the ADvance II pivotal study of DBS-f. FNM’s investors, employees and I have great confidence in Todd’s leadership and we look forward to beginning enrollment in ADvance II,” Owens said in a press release.
AxoGen said last week that it appointed Eric Sandberg as its new chief commercial officer, replacing Jon Gingrich who is set to resign effective February 15.
Prior to his time with AxoGen, Sandberg held leadership roles at various medtech firms including Guidant, CardioDx, Tangent Medical and Boston Scientific, the Alachua, Fla.-based company said.
“We are excited to welcome Eric to our executive team; his breadth of commercialization experience and proven track record of execution will be invaluable as we introduce new applications and launch new products that expand and enhance our platform for nerve repair. Eric’s executive leadership will be instrumental as AxoGen continues to transform peripheral nerve repair and create a new standard of care,” prez & CEO Karen Zaderej said in a press release.
“AxoGen has an outstanding culture of innovation and excellence, and I look forward to building upon the company’s strong foundation. AxoGen has a tremendous opportunity to improve outcomes and quality of life for patients suffering the debilitating effects of peripheral nerve damage, across a growing range of applications. I am thrilled to join the Company at this critical and exciting time, as we pursue and develop these markets,” Sandberg said in a prepared statement.
- Ra Medical taps Forgarty as CCO
- iCad names Areglado interim CFO
- Cirtec CFO Heher moves to DenMat
- Biocoat appoints Bell as CFO
- Vascular Dynamics taps Rothman as chief medical officer
- Cardinal Health names Rice as CIO
- SPR Therapeutics taps Staats as chief medical advisor
- Georgia Bio appoints Santoro as biz dev, external affairs VP